NAV	Nucleic acid-based vaccines
TAA	Tumor-associated antigens
TSA	Tumor specific antigens
CDC	Complement-mediated cytotoxicity
ADCC	Antibody-dependent cellular cytotoxicity
APC	Antigen presenting cell
DC	Dendritic cell
HLA	Human leukocyte antigen
NCCN	National Comprehensive Cancer Network
VNTR	Variable number of tandem repeats
MUC1	Mucin 1
TIL	Tumor infiltrating lymphocytes
PAMPs	Pathogen-associated molecular patterns
PAP	Prostatic acid phosphatase
PSA	Prostate-specific antigen
PSMA	Prostate-specific membrane antigen
PSCA	Prostate stem cell antigen
PFS	Progression-free survival
OS	Overall survival
RFS	Recurrence free survival
AE	Adverse event
TEAE	Treatment-emergent adverse events